Profile data is unavailable for this security.
About the company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-498.74m
- Incorporated2013
- Employees517.00
- LocationDenali Therapeutics Inc161 Oyster Point Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 866-8547
- Fax+1 (302) 655-5049
- Websitehttps://www.denalitherapeutics.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.64bn | 385.00 | -- | 35.84 | -- | 6.05 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.65bn | 118.00 | -- | 8.34 | -- | 273.58 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.67bn | 240.00 | -- | 3.41 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.76bn | 824.00 | 91.96 | 2.19 | 52.30 | 5.57 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.78bn | 143.00 | -- | 7.64 | -- | 39.33 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.79bn | 131.00 | -- | 2.55 | -- | 12.96 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Vera Therapeutics Inc | 0.00 | -251.94m | 2.87bn | 224.00 | -- | 6.56 | -- | -- | -3.98 | -3.98 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -56.87 | -54.55 | -61.62 | -60.06 | -- | -- | -- | -- | -- | -- | 0.1576 | -- | -- | -- | -58.50 | -- | 50.71 | -- |
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 2.88bn | 136.00 | -- | 5.15 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Disc Medicine Inc | 0.00 | -181.11m | 2.96bn | 84.00 | -- | 4.78 | -- | -- | -5.35 | -5.35 | 0.00 | 16.38 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -33.75 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | -43.08 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -237.39m | 2.97bn | 50.00 | -- | 4.15 | -- | -- | -2.12 | -2.12 | 0.00 | 6.34 | 0.00 | -- | -- | 0.00 | -28.31 | -22.44 | -29.21 | -23.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -28.02 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.08bn | 2.90k | -- | 3.05 | -- | 3.39 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Denali Therapeutics Inc | 0.00 | -498.74m | 3.12bn | 517.00 | -- | 3.17 | -- | -- | -2.91 | -2.91 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -39.75 | -16.91 | -42.77 | -19.81 | -- | -- | -- | -135.24 | -- | -- | 0.006 | -- | -100.00 | -- | -191.12 | -- | -2.35 | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -306.33m | 3.12bn | 316.00 | -- | 5.57 | -- | 416.15 | -3.88 | -3.88 | 0.0952 | 7.26 | 0.0104 | -- | 8.57 | 23,734.18 | -42.44 | -22.00 | -44.53 | -22.93 | -- | -- | -4,084.45 | -1,082.36 | -- | -- | 0.00 | -- | -- | -- | -28.48 | -- | 19.92 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.40bn | 233.00 | -- | 7.14 | -- | 153.83 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Denali Therapeutics Inc's reporting currency: US Dollar USD
44.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Dec 2025 | 12.31m | 7.88% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.90m | 7.62% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 10.13m | 6.49% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 5.64m | 3.61% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 5.46m | 3.50% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Sep 2025 | 5.36m | 3.43% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 5.00m | 3.20% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2025 | 4.76m | 3.05% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 4.43m | 2.84% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 3.95m | 2.53% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
